WO1996016163A3 - Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung - Google Patents

Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung Download PDF

Info

Publication number
WO1996016163A3
WO1996016163A3 PCT/DE1995/001699 DE9501699W WO9616163A3 WO 1996016163 A3 WO1996016163 A3 WO 1996016163A3 DE 9501699 W DE9501699 W DE 9501699W WO 9616163 A3 WO9616163 A3 WO 9616163A3
Authority
WO
WIPO (PCT)
Prior art keywords
embryonal
cardiac muscle
muscle cells
particular
gene
Prior art date
Application number
PCT/DE1995/001699
Other languages
English (en)
French (fr)
Other versions
WO1996016163A2 (de
Inventor
Wolfgang-Michael Franz
Anna M Wobus
Original Assignee
Wolfgang-Michael Franz
Inst Pflanzengenetik & Kultur
Anna M Wobus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DEP4441327.0 priority Critical
Priority to DE19944441327 priority patent/DE4441327C1/de
Application filed by Wolfgang-Michael Franz, Inst Pflanzengenetik & Kultur, Anna M Wobus filed Critical Wolfgang-Michael Franz
Publication of WO1996016163A2 publication Critical patent/WO1996016163A2/de
Publication of WO1996016163A3 publication Critical patent/WO1996016163A3/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061Muscle cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657Cardiomyocytes; Heart cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073Stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/80Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85Vector systems having a special element relevant for transcription from vertebrates mammalian
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Abstract

Die Erfindung betrifft embryonale (kardiomyozytäre und kardiomyoblastäre) Herzmuskelzellen, ihre Herstellung und ihre Verwendung, insbesondere zur zellvermittelten Gentransplantation. Anwendungsgebiete der Erfindung sind die Medizin und die Gentechnik. Die embryonalen Herzmuskelzellen gemäß der Erfindung enthalten zwei Genkonstrukte aus a) regulatorischer, 2,1 kb langer DNA-Sequenz des ventrikelspezifischen Myosin-Leicht-Kette-2 (MLC-2v) Promotors, dem selektionierbaren Markergen β-Galaktosidase in Fusion mit dem Reportergen Neomycin und aus b) regulatorischer DNA-Sequenz des Herpes-simplex-Virus-Thymidinkinase-Promotors und den selektionierbaren Markergen Hygromycin, sowie ggf. immortalisierende Gene und/oder ggf. durch homologe Rekombination inaktivierte Gene und/oder ggf. ein oder mehrere therapeutische Gene. Sie können vorteilhaft zur zellvermittelten Gentransplantation, insbesondere zum Aufbau gesunden Gewebes und zur Unterstüzung kontraktiler Funktionen, zur Untersuchung von Substanzen, insbesondere für pharmakologische Untersuchungen und für den Transfer therapeutischer Gene in das Myokard eingesetzt werden.
PCT/DE1995/001699 1994-11-22 1995-11-21 Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung WO1996016163A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DEP4441327.0 1994-11-22
DE19944441327 DE4441327C1 (de) 1994-11-22 1994-11-22 Embryonale Herzmuskelzellen, ihre Herstellung und ihre Verwendung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/849,706 US5928943A (en) 1994-11-22 1995-11-21 Embryonal cardiac muscle cells, their preparation and their use
EP95940117A EP0787182A2 (de) 1994-11-22 1995-11-21 Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung

Publications (2)

Publication Number Publication Date
WO1996016163A2 WO1996016163A2 (de) 1996-05-30
WO1996016163A3 true WO1996016163A3 (de) 1996-07-18

Family

ID=6533720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1995/001699 WO1996016163A2 (de) 1994-11-22 1995-11-21 Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung

Country Status (4)

Country Link
US (1) US5928943A (de)
EP (1) EP0787182A2 (de)
DE (1) DE4441327C1 (de)
WO (1) WO1996016163A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602301A (en) 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
EP0862644A2 (de) * 1995-11-17 1998-09-09 Franz, Wolfgang-M., Dr. Gentherapeutisches nukleinsäurekonstrukt, seine herstellung und verwendung zur behandlung von herzerkrankungen
US6102926A (en) 1996-12-02 2000-08-15 Angiotrax, Inc. Apparatus for percutaneously performing myocardial revascularization having means for sensing tissue parameters and methods of use
US6051008A (en) 1996-12-02 2000-04-18 Angiotrax, Inc. Apparatus having stabilization members for percutaneously performing surgery and methods of use
US6120520A (en) 1997-05-27 2000-09-19 Angiotrax, Inc. Apparatus and methods for stimulating revascularization and/or tissue growth
CA2324350A1 (en) * 1998-03-23 1999-09-30 Zymogenetics, Inc. Cardiac-derived stem cells
US20030113301A1 (en) * 1999-07-23 2003-06-19 Albert Edge Muscle cells and their use in cardiac repair
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
DE10014690A1 (de) * 2000-03-24 2001-10-18 Franz Wolfgang M Verfahren zur Isolierung in vito differenzierter Körperzellen
US8308708B2 (en) 2003-07-15 2012-11-13 Abbott Cardiovascular Systems Inc. Deployment system for myocardial cellular material
AU7342101A (en) 2000-07-13 2002-01-30 Bioheart Inc Deployment system for myocardial cellular material
US7862810B2 (en) * 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20110091428A1 (en) * 2000-07-31 2011-04-21 New York Medical College Compositions of adult organ stem cells and uses thereof
AU8469501A (en) * 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
DE10136702B4 (de) 2000-12-27 2004-04-22 Axiogenesis Ag System zur zell- und entwicklungsspezifischen Selektion differenzierender embryonaler Stammzellen, adulter Stammzellen und embryonaler Keimbahnzellen
AU2002217164B9 (en) * 2000-12-27 2006-02-09 Axiogenesis Ag System for the cell-specific and development-specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells
EP1367899A4 (de) * 2001-02-14 2004-07-28 Leo T Furcht Multipotente adulte stammzellen, ausgangsmaterial dafür, verfahren zu ihrer gewinnung und erhaltung, differenzierungsmethoden dafür, verfahren zu ihrer verwendung, sowie von ihnen stammende zellen
WO2003001202A1 (en) * 2001-06-25 2003-01-03 Cardion Ag Methods and cell populations for identifying and validating genomic targets, and for drug screening
WO2003006950A2 (en) * 2001-07-12 2003-01-23 Geron Corporation Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
US7732199B2 (en) 2001-07-12 2010-06-08 Geron Corporation Process for making transplantable cardiomyocytes from human embryonic stem cells
EP1414978A1 (de) * 2001-08-02 2004-05-06 ALTANA Pharma AG Neues rekombinantes genexpression verfahren durch stop codon suppression
DE10144326B4 (de) * 2001-09-10 2005-09-22 Siemens Ag Verfahren und System zur Überwachung eines Reifenluftdrucks
US6893431B2 (en) * 2001-10-15 2005-05-17 Scimed Life Systems, Inc. Medical device for delivering patches
US8574195B2 (en) * 2002-06-10 2013-11-05 Advanced Cardiovascular Systems, Inc. Systems and methods for detecting tissue contact and needle penetration depth using static fluid pressure measurements
US7364567B2 (en) * 2002-06-10 2008-04-29 Abbott Cardiovascular Systems Inc. Systems and methods for detecting tissue contact and needle penetration depth
MXPA05000283A (es) * 2002-07-26 2005-03-31 Wisconsin Alumni Res Found Cardiomiocitos funcionales de celulas madre embrionicas de humano.
AU2003257203A1 (en) * 2002-08-06 2004-02-23 Genvec, Inc. Improved injection system
JP2004246317A (ja) * 2002-12-20 2004-09-02 Hitachi Ltd 冷陰極型フラットパネルディスプレイ
ES2584428T3 (es) 2003-06-20 2016-09-27 Axiogenesis Ag Modelado de tejidos en un sistema de células madre embrionarias (ES)
US8426200B2 (en) * 2003-07-02 2013-04-23 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7452718B2 (en) * 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
US20050214938A1 (en) * 2004-03-26 2005-09-29 Gold Joseph D Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function
ES2701704T3 (es) 2004-04-07 2019-02-25 Ncardia Ag Sistemas de ensayo tisulares funcionales no invasivos in vitro
WO2005108598A1 (en) 2004-05-11 2005-11-17 Axiogenesis Ag Assay for drug discovery based on in vitro differentiated cells
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
WO2007002136A2 (en) 2005-06-22 2007-01-04 Geron Corporation Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells
US9005964B2 (en) * 2006-11-24 2015-04-14 Regents Of The University Of Minnesota Endodermal progenitor cells
CA2712891A1 (en) 2008-01-30 2009-08-06 Corning Incorporated Synthetic surfaces for culturing stem cell derived cardiomyocytes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012233A1 (en) * 1991-12-16 1993-06-24 The University Of North Carolina At Chapel Hill Mammalian cell-based dna libraries

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012233A1 (en) * 1991-12-16 1993-06-24 The University Of North Carolina At Chapel Hill Mammalian cell-based dna libraries

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DE WET J.R. ET AL.: "Firefly luciferase gene: structure and expression in mammalian cells", MOLECULAR AND CELLULAR BIOLOGY, vol. 7, no. 2, 1987, WASHINGTON US, pages 725 - 737, XP002001051 *
ENGELMANN GL ET AL: "Formation of fetal rat cardiac cell clones by retroviral transformation: retention of select myocyte characteristics.", J MOL CELL CARDIOL, FEB 1993, 25 (2) P197-213, ENGLAND, XP000568169 *
HUNTER J. ET AL.: "Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 39, 1995, MD US, pages 23173 - 23178, XP002001049 *
LEE K.J. ET AL.: "Myosing light chain-2 luciferase transgenic mice reveal distindt regulatory programs for cardiac and skeletal muscle-specific expression of a single contractile protein gene", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 22, 1992, MD US, pages 15875 - 15885, XP002001050 *
WOBUS A M ET AL: "Retinoic acid induces expression of the ventricular 2.1 kb myosin-light-chain-2 promoter during in vitro cardiogenesis of embryonic stem cells", CIRCULATION, 92 (8 SUPPL.). 1995. I114., XP002001047 *

Also Published As

Publication number Publication date
US5928943A (en) 1999-07-27
EP0787182A2 (de) 1997-08-06
DE4441327C1 (de) 1995-11-09
WO1996016163A2 (de) 1996-05-30

Similar Documents

Publication Publication Date Title
Gunning et al. A human beta-actin expression vector system directs high-level accumulation of antisense transcripts
Hammerschmidt et al. Genetic analysis of immortalizing functions of Epstein–Barr virus in human B lymphocytes
Tokino et al. p53 tagged sites from human genomic DNA
McGrory et al. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5
Unger et al. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.
Ehrlich DNA cloning in Bacillus subtilis
Südhof et al. 42 bp element from LDL receptor gene confers end-product repression by sterols when inserted into viral TK promoter
Oda et al. Molecular cloning and functional analysis of a new activin β subunit: a dorsal mesoderm-inducing activity in Xenopus
US4650764A (en) Helper cell
ES2338952T3 (es) Uso de una secuencia de nucleotidos que codifica la enzima i-sce i.
DE69534591T2 (de) Adenovirusfaser mit hinzugefügten liganden
Challberg A method for identifying the viral genes required for herpesvirus DNA replication
Sandri-Goldin et al. A herpesvirus regulatory protein appears to act post-transcriptionally by affecting mRNA processing.
US7094583B2 (en) Nucleic acid delivery
Grange et al. Cell-type specific activity of two glucocorticoid responsive units of rat tyrosine aminotransferase gene is associated with multiple binding sites for C/EBP and a novel liver-specific nuclear factor
JP3770333B2 (ja) 組換えdnaウイルスおよびその製造方法
Davison et al. Nucleotide sequences of the joint between the L and S segments of herpes simplex virus types 1 and 2
Feng et al. Site-specific chromosomal integration in mammalian cells: highly efficient CRE recombinase-mediated cassette exchange
EP1648481B1 (de) Virale vektoren
DE60303218T2 (de) Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
Rosen et al. Location of cis-acting regulatory sequences in the human T-cell leukemia virus type I long terminal repeat
Karlsson et al. A mutational analysis of the insulin gene transcription control region: expression in beta cells is dependent on two related sequences within the enhancer
Ueba et al. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells
DE69829287T2 (de) Verbesserung der verabreichung der nukleinsäure in zellen der plurizellulären eukaryotischen organismen und kombination zur durchführung des verfahrens
Amann et al. ‘ATG vectors’ for regulated high-level expression of cloned genes in Escherichia coli

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995940117

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995940117

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08849706

Country of ref document: US